anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Existing literature suggests that psychological and functional impairment, independent of head injury severity, can increase suicide risk. This study explores the impacts of self-perceived dysfunction within four neurobehavioral symptom clusters-vestibular (e.g., dizziness, balance), somatosensory (e.g., headaches, nausea, vision), affective (e.g., anxious, irritable mood), and cognitive (e.g., concentration, memory, indecision)-on current suicidal ideation and the perceived likelihood of future suicidal ideation and attempts. Community participants (n = 309; Mage = 36.88; 51.6% female; 79.6% White) completed the Neurobehavioral Symptom Inventory (NSI) and the Self-Injurious Thoughts and Behaviors-Short Form (SITBI-SF). Quantile regression analysis was used to explore the effects of the four neurobehavioral symptom clusters at different levels of suicidal ideation intensity, perceived likelihood of future suicidal ideation, and self-perceived likelihood of future suicide attempt. Controlling for past head injuries and suicide attempts, affective symptoms were significantly associated with a moderate and high average intensity of current suicidal ideation. Somatosensory symptoms were significantly associated with a moderate perceived likelihood of future suicidal ideation. Finally, vestibular symptoms were significantly associated with a moderate perceived likelihood of a future suicide attempt. These findings highlight the critical need to consider a broader spectrum of symptoms, including chronic physical symptoms, when assessing suicide risk. Furthermore, they underscore the need to expand beyond affective symptoms as an explanation for increased suicidality and examine additional mechanisms through which chronic physical symptoms can increase suicide risk.
The virtual reality system comprises an information processing device, a virtual reality headset, a biological data acquisition device, a No. 1 sensor and a No. 2 sensor. The information processing device generates virtual reality content according to the received instruction sent by the controller. The virtual reality headset is worn on the user and displays the received virtual reality content sent by the information processing device to the user. The biological data acquisition device acquires biological data of a user. The 1 st sensor generates 1 st position information and 1 st orientation information of the biological data collecting apparatus. The 2 nd sensor generates 2 nd position information and 2 nd orientation information of the virtual reality headset. The information processing apparatus adds a screen indicating the position and orientation of the user-recognition biological-body data collection apparatus wearing the virtual reality headset to the virtual reality content based on the 1 st and 2 nd position information and the 1 st and 2 nd orientation information.
BACKGROUND: Hospital-acquired bacterial infections are associated with high morbidity and mortality rates in patients with systemic lupus erythematosus (SLE). This study aimed to develop and validate predictive models for the risk of hospital-acquired bacterial infections in patients with SLE.
METHODS: A historical cohort study was designed for development, and another bidirectional cohort study was used for external validation. The risk of bacterial infection was assessed upon admission and after 5 days of hospitalization. Predictor selection employed the least absolute shrinkage and selection operator (LASSO) techniques. Multiple imputations were used to handle missing data. Logistic regression models were applied, and the properties of discrimination, calibration, and decision curve analysis were evaluated.
RESULTS: The development cohort comprised 1686 patients and 237 events (14.1%) from 3 tertiary hospitals. The external validation cohort included 531 patients and 84 infection outcomes (15.8%) from 10 hospital centers in Colombia (secondary and tertiary level). The models applied at admission and after 120 hours of stay exhibited good discrimination (AUC > 0.74). External validation demonstrated good performance among patients from the same tertiary institutions where the models were developed. However, geographic validation at other institutions has been suboptimal.
CONCLUSIONS: Two predictive models for nosocomial bacterial infections in patients with SLE are presented. All infection prevention recommendations should be maximized in patients at moderate/high risk. Further validation studies in diverse contexts, as well as clinical impact trials, are necessary before potential applications in research and clinical care.
Retrospective case series study. A retrospective chart review was conducted, which included demographics (age and gender) and several parameters for both the first and second eyes: surgery date, axial length, keratometric corneal power in 2 meridians, predicted intra-ocular lens (IOL) power recommended for plano target in each formulae (HofferQ, SRK II, SRK/T and Holladay 1), implanted IOL power, predicted post-operative refraction for the implanted IOL for the 4 formulae, observed post-operative refraction in spherical equivalent and post-operative best corrected visual acuity. The prediction error was calculated for the first eye (PE1) as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted IOL. This was obtained for the 4 formulae. The prediction error for the second eye (PE2) was obtained in a similar fashion. The optimal partial adjustment for second eye refinement was obtained subtracting a portion of the PE1 from the PE2 (PE2-xPE1, where 0≤x≤1) for the 4 formulae. The optimal correction factor was determined for all formulae by using an array of different proportions of PE1 that were applied to the second eye. The values ranged from 10% to 100%, with increments of 10% each.
The efficacy and safety of KEVZARA in PMR were assessed in a randomized, double-blind, placebo-controlled, 52-week, multicenter study (Study 3) (NCT03600818) in adults with PMR diagnosed according to American College of Rheumatology/European Union League against Rheumatism (ACR/EULAR) classification criteria. Patients had at least one episode of unequivocal PMR flare while attempting to taper corticosteroids.

In Study 3, patients with active PMR were randomized to receive KEVZARA 200 mg every two weeks with a pre-defined 14-week taper of prednisone (n= 60) or placebo every two weeks with a pre-defined 52-week taper of prednisone (n=58). One participant was randomized but not treated in the KEVZARA 200 mg arm. Patients experiencing a disease flare or unable to adhere to the assigned prednisone tapering schedule could receive corticosteroids as rescue therapy.

The primary endpoint was the proportion of patients with sustained remission at Week 52. Sustained remission was defined as achievement of disease remission no later than Week 12, absence of disease flare from Week 12 through Week 52, sustained reduction of CRP (to <10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52. An additional endpoint was total cumulative corticosteroid dose over 52 weeks.

Clinical Response

The proportion of participants achieving sustained remission at Week 52 was higher in the KEVZARA arm compared to the placebo arm; this difference was statistically significant. At 52 weeks, a higher proportion of patients in the KEVZARA arm achieved each component of the sustained remission endpoint compared to the placebo. An analysis was conducted that removed all acute phase reactants (CRP and ESR) criteria from the definition of the sustained remission, given sarilumab's direct impact on acute phase reactants. The results of this analysis were consistent with the primary analysis (see Table 8).

Effect on Concomitant Corticosteroid Use

The total actual cumulative corticosteroid dose included all corticosteroids taken during the study (i.e., prednisone taper regimen per protocol, add-on prednisone prior to Week 12, corticosteroid use due to rescue, or corticosteroid use during the treatment period to manage an adverse reaction not related to PMR). The total actual cumulative prednisone equivalent corticosteroid dose was lower in the KEVZARA arm (mean [SD] 1039.5 [612.2] mg and median 777 mg) relative to the placebo arm (mean [SD] 2235.8 [839.4] mg and median 2044 mg).
<P>PROBLEM TO BE SOLVED: To provide an oral preparation in which the bitterness of medicinal components is effectively inhibited or reduced.  <P>SOLUTION: The oral preparation comprises (i) the medicinal components with bitterness, (ii) acidic mucosaccharides, (iii) a refreshing agent and (iv) a sweetening agent. The acidic mucosaccharides (ii) may be a substance such as at least one selected from the group consisting of carrageenan, glycosaminoglycans, alginic acid or its salt, acidic vegetable gum and microbiologically-produced acidic gum. The refreshing agent (iii) may be a substance such as at least one terpene compound selected from menthol, camphor and borneol, or an essential oil, extract or powder containing the above terpene compound. The sweetening agent (iv) may be at least one selected from saccharine, aspartame, acesulfame, sucralose, glycyrrhizic acid, stevia, thaumatin and their salts.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The active ingredient in gabapentin capsules is gabapentin, USP which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid.

The molecular formula of gabapentin is C9H17NO2 and a molecular weight is 171.24. The structural formula of gabapentin is:

Gabapentin, USP is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is –1.25.

Gabapentin Capsules, USP are supplied as imprinted hard gelatin capsules containing 100 mg, 300 mg and 400 mg of gabapentin, USP.

The inactive ingredients are mannitol, pre-gelatinized starch and talc. The 100 mg capsule shell contains titanium dioxide. The 300 mg capsule contains FD&C Red 40, D&C Yellow 10 and titanium dioxide. The 400 mg capsule shell contains FD&C Red 40, D&C Yellow 10 and titanium dioxide.
Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery).
Infants receive genome sequencing with analysis of approximately 1000 genes associated with childhood-onset and highly actionable adult-onset disease risks. Pathogenic and likely pathogenic variants are reported to the child's parents and pediatrician. Participants also receive a detailed family history report and standard well-child care.
PURPOSE: To obtain the subject new substance produced by microorganisms belonging to the genus Agrobacterium, excellent in xanthine oxidase inhibiting action and useful for improvement and prevention of hyperuricemia and as a medicine for gout. CONSTITUTION: This compound is 4-amino-6-hydroxy-1H- pyrazolo[3,4-α]pyrimidin-3-one expressed by the formula. the compound has the following physicochemical properties. Appearance: white needle-like crystal; molecular weight: 167; molecular formula: C5 H5 N5 O2 ; UV spectrum: λmax 298nm (pH 12.6), etc. The compound of the formula is obtained by culturing a microorganism belonging to the genus Agrobacterium and having hydroxyakalone producing activity, e.g. Agrobacterium aurantiacus N-81106 strains (FERM P-14023) in a culture medium and harvesting from cultured products. Furthermore, preferable culture temperature is 16-37 deg.C, especially 22-30 deg.C and preferable pH is 4-10, especially 6-8 and the compound is preferably cultured in liquid culture for 1-8 days.
Patients receive ceritinib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
SYNGAP1-ID is a neurodevelopmental disorder caused by a mutation of the SYNGAP1 gene. Characterized by moderate to severe developmental delay, it is associated with several physical and behavioral issues as well as additional diagnoses, including autism. However, it is not known whether social cognitive differences seen in SYNGAP1-ID are similar to those previously identified in idiopathic or other forms of autism. This study therefore investigated visual social attention in SYNGAP1-ID. Eye movements were recorded across three passive viewing tasks (face scanning, pop-out, and social preference) of differing social complexity in 24 individuals with SYNGAP1-ID and 12 typically developing controls. We found that SYNGAP1-ID participants looked at faces less than the controls, and when they did look at faces, they had less time looking at and fewer fixations to the eyes. For the pop-out task, where social and nonsocial objects (Phone, car, face, bird, and face-noise) were presented in an array, those with SYNGAP1-ID spent significantly less time looking at the phone stimulus as well as fewer fixations to the face compared with the typically developing controls. When looking at two naturalistic scenes side by side, one social in nature (e.g., with children present) and the other not, there were no differences between the SYNGAP1-ID group and typically developing controls on any of the examined eye tracking measures. This study provides novel findings on the social attention of those with SYNGAP1-ID and helps to provide further evidence for using eye tracking as an objective measure of the social phenotype in this population in future clinical trials.
Participants will receive daily dose of ASP1570 in a 21-day cycle. pembrolizumab will be administered every 6 weeks on day 1 of every other ASP1570 cycle.
Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.
A therapeutic delivery system uses an engineered extracellular vesicle-albumin hybrid carrier for curcumin, which is embedded in dissolvable microneedle arrays. The co-encapsulation of curcumin with albumin in extracellular vesicles extends curcumin's stability. The incorporation of therapeutic loaded carrier into microneedle arrays does not alter its cell uptake properties or bioactivity. Moreover, the bioactivity of therapeutic loaded carrier can be preserved for at least one year when encapsulated in microneedle arrays and stored under room temperature storage conditions. The microneedle arrays of the delivery system are fabricated using molding and casting processes. The extracellular vesicle carrier can be loaded using sonication.
Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
A burns carbuncle poison plaster and a preparation method of the burns carbuncle poison plaster are disclosed. The invention relates to a medicine capable of effectively treating burn and scald of human body surface, carbuncle, cellulitis, furuncle, swelling, nominate and innominate pyogenic infections and traumatic injury, particularly to a combined medicine prepared from traditional Chinese medicinal herbs. The invention also relates to a preparation method of the medicine. The medicine has the following formula: 100-150g of Chinese angelica, 100-150g of Rheum officinale, 100-150g of red peony roots, 100-150g of rehmannia roots, 100-150g of Chinese cinnamon, 100-150g of Cochinchina momordica seeds, 100-150g of Radix scrophulariae, 100-150g of Angelica officinalis, 10-15g of olibanum, 10-15g of myrrh, and 2000g of minium. The preparation method comprises the steps of soaking the above Chinese medicinal materials in balm, decocting with mild fire, sufficiently stirring, soaking in cold water, and making into plaster. According to the practical use, the plaster provided by the invention has mystical curative effects on burn and scald, osteomyelitis, herpes zoster and other innominate pyogenic infections, scabies, and the like, and has no toxic adverse effect. In addition, the medicinal materials used in the plaster of the invention are all common traditional Chinese medicinal herbs with low price.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to development of agent with broad range of pharmacological effect. Agent with antiviral, antitumor, immunomodulating and anti-inflammatory effects is 40% alcohol tincture containing turf, coal, garlic, rose fruit and bee honey at the ratio of an aqueous-spirituous mixture to the composition of active components 10:1. Agent can be used both orally and externally. EFFECT: good therapeutic effect in different diseases. 4 cl
Risk Summary

Data from published case series and case reports describe Fludeoxyglucose F 18 Injection crossing the placenta with uptake by the fetus (see Data). All radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. However, published studies that describe Fludeoxyglucose F 18 Injection use in pregnant women have not identified a risk of drug-associated major birth defects, miscarriage, or adverse maternal or fetal outcomes. If considering Fludeoxyglucose F 18 Injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from Fludeoxyglucose F 18 Injection and the gestational timing of exposure.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.

Data

Human Data

Data from published case series and case reports describe Fludeoxyglucose F 18 Injection crossing the placental barrier and visualization of radioactivity throughout the body of the fetus. The estimated fetal absorbed radiation dose from the maximum labeled dose (370 MBq) of Fludeoxyglucose F 18 was 10 mGy with first trimester exposure to PET alone and 20mGy with first trimester exposure to PET/CT scan combination. Long-term adverse radiation effects to a child exposed to Fludeoyxglucose F 18 Injection in utero are unknown. No adverse fetal effects or radiation-related risks have been identified for diagnostic procedures involving less than 50 mGy, which represents less than 20 mGy fetal doses.
Peginterferon beta-1alfa will be made available from Biogen Inc. Switzerland. 125 micrograms of pegylated IFNß1alfa (PLEGRIDY, Biogen) administered on Study Days 1, 6 and 11 (i.e. for a total of 3 doses) via subcutaneous injection.
China is one of the countries with high burden of tuberculosis (TB) defined by WHO. IVF-ET is an effective method to treat infertility. Chest X-ray is a routine examination before IVF-ET, which can exclude active tuberculosis. However, for patients with chest X-ray showing old healed tuberculosis, the relationship between latent tuberculosis infection (LTBI) and pregnancy outcomes is unknown. In this study, a prospective cohort study was carried out in infertile women who were planning to receive IVF-ET. IGRA were tested in patients with old tuberculosis in chest X-ray. A cohort of IGRA positive and IGRA negative was constructed. The pregnancy outcomes were followed up prospectively and the relationship between latent infection of tuberculosis and pregnancy outcomes was analyzed. The primary outcome was clinical pregnancy rate, miscarriage rate and live birth rate. Secondary outcomes were tuberculosis reactivation during pregnancy period and in 3 months after delivery.
The invention provides a composition containing 1H-pyrazolo [3,4-D]PyrimidineCDK8 inhibitors of the structure, compounds which are cyclin dependent kinase 8 inhibitors, have novel chemical structures and possess 1H-pyrazolo [3,4-D]Pyrimidine structures. The compound is a structure shown in a general formula (I) or pharmaceutically acceptable salt thereof; the invention also provides a preparation method of the compound. The inhibitor binds to the DMG-out conformation of the CDK8 target and belongs to class II inhibitors. Its IC50 value for CDK8 reaches 2.3nM, which is comparable to the current highly active type I inhibitors with a residence time of 950 minutes. The inhibitor was not active on 19 kinases similar to CDK8 at a concentration of 1 μm, thus exhibiting high selectivity for CDK 8. And has lower toxicity as a medicament.
A new OrAnom1 gene introgressed in cultivated sunflower from wild Helianthus anomalus confers late post-attachment resistance to Orobanche cumana race G and maps to a target interval in Chromosome 4 where two receptor-like kinases (RLKs) have been identified in the H. anomalus genome as putative candidates. Sunflower broomrape is a parasitic weed that infects sunflower (Helianthus annuus L.) roots causing severe yield losses. Breeding for resistance is the most effective and sustainable control method. In this study, we report the identification, introgression, and genetic and physiological characterization of a new sunflower source of resistance to race G of broomrape developed from the wild annual sunflower H. anomalus (accession PI 468642). Crosses between PI 468642 and the susceptible line P21 were carried out, and the genetic study was conducted in BC1F1, BC1F2, and its derived BC1F3 populations. A BC1F5 germplasm named ANOM1 was developed through selection for race G resistance and resemblance to cultivated sunflower. The resistant trait showed monogenic and dominant inheritance. The gene, named OrAnom1, was mapped to Chromosome 4 within a 1.2 cM interval and co-segregated with 7 SNP markers. This interval corresponds to a 1.32 Mb region in the sunflower reference genome, housing a cluster of receptor-like kinase and receptor-like protein (RLK-RLP) genes. Notably, the analysis of the H. anomalus genome revealed the absence of RLPs in the OrAnom1 target region but featured two RLKs as possible OrAnom1 candidates. Rhizotron and histological studies showed that OrAnom1 determines a late post-attachment resistance mechanism. Broomrape can establish a vascular connection with the host, but parasite growth is stopped before tubercle development, showing phenolic compounds accumulation and tubercle necrosis. ANOM1 will contribute to broadening the genetic basis of broomrape resistance in the cultivated sunflower pool and to a better understanding of the molecular basis of the sunflower-broomrape interaction.